한미약품, 릴리에 1조9000억 규모 신약 기술이전

This $1.26 billion partnership validates the global commercial potential of Korean biotech innovations, particularly Hanmi's LAPSCOVERY platform for extended-duration therapeutics. The deal reflects growing pharmaceutical industry demand for GLP-2 analogs and signals that major multinational companies now recognize Korean-developed biologics as worthy of significant investment. For investors and biotech stakeholders, this demonstrates that Korean firms can command premium licensing deals on the global stage.